Fibrinogen: A novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (Italian melanoma inter-group) trial

Journal of Translational Medicine

Volumn 1, Issue , 2003, Pages

  Guida, Michele ^a   Ravaioli, Alessandra ^b   Sileni, Vanna Chiarion ^c   Romanini, Antonella ^d   Labianca, Roberto ^e   Freschi, Antonio ^f   Brugnara, Salvatore ^g   Casamassima, Addolorata ^a   Lorusso, Vito ^a   Nanni, Oriana ^b   Ridolfi, Ruggero ^h   Ridolfi, Laura ^h   Redelotti, Roberta ^c   Artioli, Grazia ^c   Tanganelli, Lucia ^d   Poletti, Paola ^e   Porrozzi, Stella ⁱ   Corgna, Enrichetta ⁱ   Lo Presti, Giuseppe ^j   Iacono, Carmelo ^j   Chiara, Anna ^k   Luchena, Giovanna ^k   Scelzi, Elvira ^l   Manente, Paolo ^l   Scaltriti, Laura ^m   Artioli, Fabrizio ^m   Palmeri, Sergio ⁿ   Miceli, Salvatore ⁿ   Muggiano, Antonio ^o   Montanara, Sergio ^p   Cozzi, Sergio ^p   Pari, Franca ^q   Aitini, Enrico ^q   Mascia, Vittorio ^o   Farci, Daniele ^o   Gambi, Angelo ^r   Cappelli, Maria Cristina ^r   De Toma, Domenico ^s   Giacobone, Anna ^s   Bertuccelli, Maurizio ^t   Biasco, Guido ^u   Casadei, Simona ^u   Toma, Salvatore ^v   more..

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^c Department of Medical Oncology   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e Division of Anaesthesia   (Italy)

^f CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^g SANTA CHIARA HOSPITAL   (Italy)

^h MORGAGNI PIERANTONI HOSPITAL   (Italy)

ⁱ ASLnZ   (Italy)

^j Ragusa Hospital   (Italy)

^k SANT ANNA HOSPITAL   (Italy)

^l Nuclear Medicine PET Center   (Italy)

^m B Ramazzini Hospital   (Italy)

ⁿ UNIVERSITY OF PALERMO   (Italy)

^o Ospedale Oncologico A Businco   (Italy)

^p Castelli Hospital   (Italy)

^q per gli Infermi Hospital ^*  (Italy)

^r Ospedale per gli Infermi di Faenza   (Italy)

^s San Donato Polyclinic and Institute for Research and Care   (Italy)

^t Ospedale Riuniti   (Italy)

^u UNIVERSITY OF BOLOGNA   (Italy)

^v UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; C REACTIVE PROTEIN; CARMUSTINE; CISPLATIN; DACARBAZINE; FIBRINOGEN; INTERLEUKIN 2; LACTATE DEHYDROGENASE;

AGE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL PROTECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLYSIS; EOSINOPHIL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH STATUS; HEMATOPOIETIC SYSTEM; HOST; HUMAN; INTERMETHOD COMPARISON; ITALY; LEUKOCYTE COUNT; LIVER DISEASE; LYMPHOCYTE COUNT; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NATURAL KILLER CELL; NONBIOLOGICAL MODEL; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; PREDICTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT OUTCOME; TUMOR LOCALIZATION;

EID: 4344700015     PISSN: 14795876     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-5876-1-13     Document Type: Article

References (40)

1. Parker SL, Tong T, Bolden S, et al.: Cancer statistics 1996. CA Cancer J Clin 1996, 46:5-25.
2. Greenlee RT, Hill-Harmon MB, Murray T, et al.: Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15-36.
3. Eton O, Legha SS, Bedikian AY, et al.: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002, 20:2045-2052.
4. Rosenberg SA, Yang JC, Schwrtzentruber DJ, et al.: Prospective randomised trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifene alone or in combination with interleukin-2 and interferonalpha-2b. J Clin Oncol 1999, 17:968-975.
5. Balch C, Buzaid AC, Soong SJ, et al.: Final version of the AJCC staying system for cutaneous melanoma. J Clin Onc 2001, 19:3635-3649.
6. Balch CM, Soong S, Shaw HM, et al.: An analysis of prognostic factors in 8500 patients with cutaneous melanoma. in: Cutaneous Melanoma 2 Edition (Edited by: Balch CM, Houghton AN, Milton GW). Philadelphia. PA. Lippincott 1992, 180-186.
7. Sirott MN, Bajorin DF, Wong GYC, et al.: Prognostic factors in patients with metastatic melanoma: A multivvariate analysis. Cancer 1993, 73:3091-3098.
8. Keilholz U, Scheibenbogen C, Sommer M, et al.: Prognostic factors for response and survival in patients with metastatic melanoma receiving immunothrapy. Mel Res 1996, 6:173-178.
9. Manola J, Atkins M, Ibrahim J, Kirkwood J: Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000, 15:18-22.
10. Ryan L, Kramar A, Borden E: Prognostic factors in metastatic melanoma. Cancer 1993, 71:2995-3005.
11. Eton O, Legha SS, Moon TE, et al.: Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998, 16:1103-1111.
12. Tartour E, Blay JY, Dorval T, et al.: Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: A French multiinstitutional study. J Clin Oncol 1996, 14:1697-1703.
13. Phan GP, Attia P, Steinberg SM, et al.: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001, 19:3477-3482.
14. Hernberg M: lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy. Med Oncol 1999, 16:145-153.
15. Gunji Y, Gorelik E: Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells. Cancer Res 1988, 48:5216-5221.
16. Cardinali M, Uchini R, Chung SI: Interaction of fibrinogen with murine melanoma cells: covalent association with cell membranes and protection against recognition by lymphokine activated killer cells. Cancer Res 1990, 50:8010-8016.
17. Palumbo JS, Kombrinck KV, Drew AF, et al.: Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000, 96:3302-3309.
18. Ridolfi R, Chiaron-Sileni V, Guida M, et al.: Cisplatin, dacarbazine with or without subcutaneous interleukin-2 and alfa interferon phase III randomized trial: results of an Italian multicentric study in advanced melanoma out-patients. J Clin Onc 2002, 20:1600-1607.
19. Allen IE, Kupelnick B, Kumashiro M: Efficacy of interleukin-2 in the treatment of metastatic melanoma-systemic review and metastasis-analysis. Cancer Ther 1998, 1:168-173.
20. Keilholz U, Conradt C, Legha SS: Results of interleukin-2-based treatment in advanced melanoma: A case record-base analysis of 631 patients. J Clin Oncol 1998, 16:2921-2929.
21. Huncharek M, Caubet JF, McGarry R'01: Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001, 11(1):75-81.
22. Klein B, Wijdenes J, Zhang XG, et al.: Murine anti-interleukin 6 monoclonal antibody therapy in myeloma. Blood 1991, 78:1198-1204.
23. Baumann H, Gauldie J: The acute phase response. Immunol Today 1994, 15:74-80.
24. Gogard A, Fauchet F, Raher S, et al.: Generation of monoclonal antibodies against HILDA/LIF and their use in the quantitative assay of the cytokine. Cytokine 1993, 5:16-23.
25. Scott HR, McMillan DC, Crilly A, et al.: The relationship between weight loss and interleukin-6 in non-small cell lung cancer. Br J Cancer 1996, 73:1560-1562.
26. Blay JY, Negrier S, Combaret V, et al.: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992, 52:3317-3322.
27. Walther MM, Johnson B, Culley D, et al.: Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol 1998, 159(3):718-722.
28. Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980, 65:25-32.
29. Riesco A: Five-year cancer cure: relation to total amount of peripheral lymphocyles and neutrophils. Cancer 1970, 25:135-140.
30. Maltoni M, Pirovano M, Nanni O, et al.: Biological indices predictive of survival in 519 italian terminally ill cancer patients. J Paain Symptom Manage 1997, 13:1-9.
31. Kim US, Papatestas AE, Aufses AH: Prognostic significance of peripheral lymphocyte counts and carcinoembryonic antigens in colorectal carcinoma. J Surg Oncol 1976, 8(3):257-62.
32. Lavin P, Bruckner HW, Plaxe SC: Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer 1982, 50:2016-2023.
33. Bernengo MG, Lisa F, Meregalli M, et al.: The prognostic value of T-lymphocyte levels in malignant melanoma. A five year follow-up. Cancer 1983, 52:1841-1848.
34. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lyinphokine-activated killer cell phenomenon. J Exp Med 1982, 155:1823-1841.
35. Palmer PA, Atzpodien J, Philip T, Negrier S, et al.: A comparison of 2 modes of administration of rIL-2: continuous intravenous infusion alone versus subcutaneous administration plus IFN-a in patients with advanced renal cell carcinoma. Cancer Biother 1993, 8:123-136.
36. Gohring B, Riemann D, Rebmann U, et al.: Prognostic value of immunomonitoring of patients with renal cell carcinoma under therapy with IL- 2/IFN-alpha in combination with 5-FU. Urol Res 1996, 24:297-3031.
37. Fumagalli L, Lissoni P, Di Felice G, et al.: Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Brit J Cancer 1999, 80:407-411.
38. Monson JRT, Ramsden C, Guillou PJ: Decreased IL-2 production in patients with gastrointestinal cancer. Br J Surg 1986, 73:483-486.
39. Dvorak HF: Thombosis and cancer. Hum Pathol 1987, 18:275-281.
40. Lee SY, Park LO, Suk SH: role of fibrinogen covalently associated with cell membrane in blood-borne lung tumor colony formation of murine mammary carcinoma cells. Oncology 2000, 59:238-244.